TechBio · Cell-to-cell communication
Signaling answers that start with the patient, not the pathway.
Cellazon builds PathwayPersona™️, an automated platform that analyzes cell-to-cell communication using the patient’s single-cell RNA-Sequence data as the primary input for discovery of novel therapeutic targets and biomarkers.
Detailed protocols and platform architecture are shared under NDA. Nothing confidential is published on this site.
Where the value sits
What we deliver is the operational discipline that makes the techniques work at scale.
Our edge is the rigorous process and judgment applied around the core methods. The product is consistent, high-standard execution, not the techniques themselves. Discipline in application is what creates the actual value.
Validation hit-rate, not scoring math
Ligand–receptor scoring is a published commons. We are judged on how many inferred targets survive orthogonal validation, and we design every run so that number is measurable.
Responder versus non-responder by design
Every analysis is framed as a contrast between clinical response groups, per cell type, so results map to a decision rather than to a gene list.
Curated disease context
Generic interaction databases produce generic answers. We layer disease- and therapy-specific signaling context onto the inference so the output reflects the biology in question.
Reproducible from sample to report
Consent, access control, provenance and re-runnability are built into the platform, not bolted on for the first audit.
From sample to shortlist
Six stages, one contrast running through all of them.
The full protocol is proprietary. The shape of it is not, and we would rather you judge the shape before signing anything.
- 01
Cohort
Define the clinical question and the response groups it must separate.
- 02
Harmonize
Quality control and integration that keeps patient identity and treatment history intact.
- 03
Resolve
Annotate the cell states that actually track therapy response.
- 04
Infer
Reconstruct sender–receiver signaling and downstream pathway activity per group.
- 05
Rank
Prioritize candidates by effect size, consistency across patients, and druggability.
- 06
Validate
Test the shortlist orthogonally and report the hit-rate honestly.
Evaluating us for a program, a partnership, or an investment?
We will walk through methodology, prior work, and platform design in detail under an NDA. Tell us what you need to see and we will bring the right people to the call.
Start the conversation